06Dec 2022
β3 adrenergic agonist treatment in chronic pulmonary hypertension associated with heart failure (SPHERE‐HF): a double blind, placebo‐controlled, randomized clinical trial

β3 adrenergic agonist treatment in chronic pulmonary hypertension associated with heart failure (SPHERE‐HF): a double blind, placebo‐controlled, randomized clinical trial

Summary of the study outline, flowchart, and results of the primary and secondary outcomes. The β3 selective agonist mirabegron did not improve pulmonary haemodynamics in adult patients with combined pre‐ and post‐capillary pulmonary hypertension associated with symptomatic heart failure. On secondary outcomes, a significant improvement in right ventricular ejection fraction assessed by advanced cardiac imaging was found, without differences in functional class or quality of life. PP, per protocol population.

  • #cardiology

Like

Save

Share